Table 1 Correlation of clinicopathological patient characteristics with tumor bed ratio, and Ki67 proliferation indices.

From: Intratumoral heterogeneity affects tumor regression and Ki67 proliferation index in perioperatively treated gastric carcinoma

    

Median tumor bed ratio dichotomized

Maximum KiH

Minimum KiL

KiD max KiH min KiL

  

Total

<median (responders)

≥median (non-responders)

<median

≥median

<median

≥median

<median

≥median

  

n

(%)

n

(%)

n

(%)

n

(%)

n

(%)

n

(%)

n

(%)

n

(%)

n

(%)

Total

Gender

n p(1)

106

 

106

  

1.000

99

  

0.023(4)

97

  

0.805

97

  

0.047(4)

Male

 

85

(80.2)

42

(49.4)

43

(50.6)

35

(44.3)

44

(55.7)

39

(50.6)

38

(49.4)

34

(44.2)

43

(55.8)

Female

 

21

(19.8)

11

(52.4)

10

(47.6)

15

(75.0)

5

(25.0)

11

(55.0)

9

(45.0)

14

(70.0)

6

(30.0)

Age Group

n p(1)

106

 

106

  

0.697

99

  

0.546

97

  

1.000

97

  

0.684

<64 Years

 

49

(46.2)

23

(46.9)

26

(53.1)

24

(54.5)

20

(45.5)

22

(51.2)

21

(48.8)

20

(46.5)

23

(53.5)

≥64 Years

 

57

(53.8)

30

(52.6)

27

(47.4)

26

(47.3)

29

(52.7)

28

(51.9)

26

(48.1)

28

(51.9)

26

(48.1)

Localization

n p(1)

106

 

106

  

1.000

99

  

0.016

97

  

0.825

97

  

<0.001

Proximal stomach

 

75

(70.8)

38

(50.7)

37

(49.3)

29

(42.0)

40

(58.0)

36

(52.9)

32

(47.1)

26

(38.2)

42

(61.8)

Distal stomach

 

31

(29.2)

15

(48.4)

16

(51.6)

21

(70.0)

9

(30.0)

14

(48.3)

15

(51.7)

22

(75.9)

7

(24.1)

Laurén phenotype

n p(1)

106

 

106

  

0.042(4)

99

  

0.003

97

  

0.989

97

  

0.003

Intestinal

 

53

(50.0)

33

(62.3)

20

(37.7)

26

(55.3)

21

(44.7)

24

(53.3)

21

(46.7)

24

(53.3)

21

(46.7)

Diffuse

 

23

(21.7)

8

(34.8)

15

(65.2)

17

(73.9)

6

(26.1)

11

(47.8)

12

(52.2)

17

(73.9)

6

(26.1)

Mixed

 

21

(19.8)

10

(47.6)

11

(52.4)

5

(25.0)

15

(75.0)

10

(50.0)

10

(50.0)

4

(20.0)

16

(80.0)

Unclassifiable

 

9

(8.5)

2

(22.2)

7

(77.8)

2

(22.2)

7

(77.8)

5

(55.6)

4

(44.4)

3

(33.3)

6

(66.7)

ypT

n p(2)

106

 

106

  

<0.001

99

  

0.148

97

  

0.154

97

  

0.432

ypT1a/T1b

 

17

(16.0)

12

(70.6)

5

(29.4)

8

(66.7)

4

(33.3)

5

(41.7)

7

(58.3)

7

(58.3)

5

(41.7)

ypT2

 

16

(15.1)

12

(75.0)

4

(25.0)

10

(71.4)

4

(28.6)

5

(41.7)

7

(58.3)

9

(75.0)

3

(25.0)

ypT3

 

63

(59.4)

28

(44.4)

35

(55.6)

26

(41.3)

37

(58.7)

33

(52.4)

30

(47.6)

25

(39.7)

38

(60.3)

ypT4a/T4b

 

10

(9.4)

1

(10.0)

9

(90.0)

6

(60.0)

4

(40.0)

7

(70.0)

3

(30.0)

7

(70.0)

3

(30.0)

ypN

n p(2)

106

 

106

  

<0.001

99

  

0.095

97

  

0.084

97

  

0.133

ypN0

 

35

(33.0)

22

(62.9)

13

(37.1)

20

(64.5)

11

(35.5)

15

(50.0)

15

(50.0)

19

(63.3)

11

(36.7)

ypN1

 

23

(21.7)

16

(69.6)

7

(30.4)

9

(42.9)

12

(57.1)

5

(23.8)

16

(76.2)

7

(33.3)

14

(66.7)

ypN2

 

28

(26.4)

12

(42.9)

16

(57.1)

13

(48.1)

14

(51.9)

17

(63.0)

10

(37.0)

16

(59.3)

11

(40.7)

ypN3

 

20

(18.9)

3

(15.0)

17

(85.0)

8

(40.0)

12

(60.0)

13

(68.4)

6

(31.6)

6

(31.6)

13

(68.4)

UICC stage

n p(2)

106

 

106

  

0.003

99

  

0.003

97

  

0.087

97

  

0.003

IA/IB

 

17

(16.0)

11

(64.7)

6

(35.3)

8

(66.7)

4

(33.3)

6

(50.0)

6

(50.0)

7

(58.3)

5

(41.7)

IIA/IIB

 

16

(15.1)

13

(81.3)

3

(18.8)

12

(75.0)

4

(25.0)

3

(20.0)

12

(80.0)

13

(86.7)

2

(13.3)

IIIA/IIIB/IIIC

 

60

(56.6)

25

(41.7)

35

(58.3)

27

(46.6)

31

(53.4)

34

(58.6)

24

(41.4)

25

(43.1)

33

(56.9)

IV/IVA/IVB

 

13

(12.3)

4

(30.8)

9

(69.2)

3

(23.1)

10

(76.9)

7

(58.3)

5

(41.7)

3

(25.0)

9

(75.0)

ypL

n p(1)

106

 

106

  

<0.001

99

  

<0.001

97

  

0.828

97

  

<0.001

ypL0

 

74

(69.8)

46

(62.2)

28

(37.8)

44

(64.7)

24

(35.3)

35

(53.0)

31

(47.0)

41

(62.1)

25

(37.9)

ypL1

 

32

(30.2)

7

(21.9)

25

(78.1)

6

(19.4)

25

(80.6)

15

(48.4)

16

(51.6)

7

(22.6)

24

(77.4)

ypV

n p(1)

106

 

106

  

<0.003

99

  

0.318

97

  

1.000

97

  

0.487

ypV0

 

97

(91.5)

53

(54.6)

44

(45.4)

47

(52.2)

43

(47.8)

45

(51.1)

43

(48.9)

45

(51.1)

43

(48.9)

ypV1

 

9

(8.5)

0

(0.0)

9

(100.0)

3

(33.3)

6

(66.7)

5

(55.6)

4

(44.4)

3

(33.3)

6

(66.7)

ypPn

n p(1)

106

 

106

  

0.073

99

  

0.504

97

  

0.657

97

  

0.652

ypPn0

 

79

(74.5)

44

(55.7)

35

(44.3)

38

(52.8)

34

(47.2)

35

(50.0)

35

(50.0)

36

(51.4)

34

(48.6)

ypPn1

 

27

(25.5)

9

(33.3)

18

(66.7)

12

(44.4)

15

(55.6)

15

(55.6)

12

(44.4)

12

(44.4)

15

(55.6)

R-status

n p(1)

104

 

104

  

0.359

97

  

0.755

95

  

1.000

95

  

0.759

pR0

 

92

(88.5)

47

(51.1)

45

(48.9)

45

(52.3)

41

(47.7)

42

(50.0)

42

(50.0)

43

(51.2)

41

(48.8)

pR1

 

12

(11.5)

4

(33.3)

8

(66.7)

5

(45.5)

6

(54.5)

6

(54.5)

5

(45.5)

5

(45.5)

6

(54.5)

Becker grading

n p(2)

106

 

106

  

<0.001

99

  

<0.001

97

  

0.012

97

  

<0.001

1b

 

29

(27.4)

27

(93.1)

2

(6.9)

16

(72.7)

6

(27.3)

5

(25.0)

15

(75.0)

16

(80.0)

4

(20.0)

2

 

19

(17.9)

14

(73.7)

5

(26.3)

14

(73.7)

5

(26.3)

10

(52.6)

9

(47.4)

15

(78.9)

4

(21.1)

3

 

58

(54.7)

12

(20.7)

46

(79.3)

20

(34.5)

38

(65.5)

35

(60.3)

23

(39.7)

17

(29.3)

41

(70.7)

mTBR

n p(1)

      

99

  

0.016

97

  

0.002

97

  

0.015

<median (responder)

       

27

(58.7)

19

(41.3)

15

(34.1)

29

(65.9)

28

(63.6)

16

(36.4)

≥median (non-responder)

       

23

(43.4)

30

(56.6)

35

(66.0)

18

(34.0)

20

(37.7)

33

(62.3)

Overall Survival [months]

p(3)

96

 

96

  

0.014

90

  

0.823

88

  

0.811

88

  

0.372

Total/events/censored

 

96/52/44

46/21/25

50/31/19

44/26/18

46/24/22

45/24/21

43/25/18

43/24/19

45/25/20

Median Survival

 

26.6 ± 3.5

32.2 ± 7.6

13.2 ± 5.2

24.6 ± 3.2

22.4 ± 5.0

22.8 ± 6.5

26.6 ± 3.3

26.6 ± 4.3

22.1 ± 7.4

95% C.I.

 

[19.9 - 33.4]

[17.3 - 47.2]

[2.9 - 23.4]

[18.3 - 30.9]

[12.5 - 32.3]

[10.0 - 35.5]

[20.2 - 33.0]

[18.3 - 35.0]

[7.7 - 36.6]

Tumor Specific Survival [months]

p(3)

96

 

96

  

0.034(4)

90

  

0.742

88

  

0.801

88

  

0.478

Total/events/censored

 

96/41/55

46/17/29

50/24/26

44/20/24

46/19/27

45/17/28

43/21/22

43/19/24

45/19/26

Median Survival

 

30.9 ± 2.8

61.5 ± 27.9

22.1 ± 7.7

30.9 ± 8.8

32.0 ± 9.0

32.3 ± n.c.

27.3 ± 5.0

27.3 ± 8.9

26.7 ± 8.0

95% C.I.

 

[25.3 - 36.4]

[6.9 - 116.1]

[7.0 - 37.3]

[13.6 - 48.1]

[14.4 - 49.7]

n.c.

[17.5 - 37.2]

[10.0 - 44.7]

[11.1 - 42.3]

  1. KiH: maximum Ki67 proliferation index maximum; KiL: minimum Ki67 proliferation index; KiD: the difference between KiH/KiH; n.c. not computed, (1) Fisher’s exact test; (2) Kendall’s tau test; (3) log-rank test; (4) not significant after multiple testing correction.
Back to article page